anthrax vaccine adsorbed (AVA)

From Aaushi
Jump to navigation Jump to search

Introduction

An Al(OH)3 precipitated preparation of Bacillus anthracis protective antigen from an attenuated, non encapsulated strain of B anthracis (Sterne).

(See 'Virulence factors' under Bacillus anthracis.)

Indications

Dosage

(administration)

Notes

More general terms

Additional terms

References

  1. 1.0 1.1 Dixon TC et al Anthrax. N Engl J Med 1999, 341:815 PMID: https://www.ncbi.nlm.nih.gov/pubmed/10477781
  2. 2.0 2.1 2.2 2.3 2.4 Wright JG et al Use of Anthrax Vaccine in the United States Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009 Morbidity and Mortality Weekly Report (MMWR); July 23, 2010 / 59(rr06);1-30 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/20651644 <Internet> http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5906a1.htm corresponding NGC guideline withdrawn Jan 2016
  3. Lowes R Anthrax Vaccine Approved for Postexposure Protection. Medscape Oncology. Nov 24, 2015 http://www.medscape.com/viewarticle/854945?nlid=91968_3663&src=wnl_edit_newsal&uac=40275SJ&impID=899989&faf=1
    FDA News Release. November 23, 2015 FDA approves vaccine for use after known or suspected anthrax exposure. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm474027.htm
  4. 4.0 4.1 4.2 Bower WA, Schiffer J, Atmar RL, et al. Use of Anthrax Vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2019. MMWR Recomm Rep 0019;68(No. RR-4):1-14 https://www.cdc.gov/mmwr/volumes/68/rr/rr6804a1.htm